Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes
- Authors: Fazylov V.C.1, Tkacheva S.V.1, Manapova E.R.1, Jakupova F.M.1
-
Affiliations:
- Kazan State Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 60, No 1 (2015)
- Pages: 28-31
- Section: ORIGINAL RESEARCHES
- URL: https://journal-vniispk.ru/0507-4088/article/view/118053
- ID: 118053
Cite item
Full Text
Abstract
The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-a, interleukin-1β (IL-1β) and interferon-gamma (IFN-y) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-a and ribavirin in patients with recurrent HCV-infection.
About the authors
V. Ch. Fazylov
Kazan State Medical University, Ministry of Health of the Russian Federation
Author for correspondence.
Email: vildan47@rambler.ru
Vil’dan Fazylov, MD, PhD, DSc
420012, Kazan
Russian FederationS. V. Tkacheva
Kazan State Medical University, Ministry of Health of the Russian Federation420012, Kazan Russian Federation
E. R. Manapova
Kazan State Medical University, Ministry of Health of the Russian Federation420012, Kazan Russian Federation
F. M. Jakupova
Kazan State Medical University, Ministry of Health of the Russian Federation420012, Kazan Russian Federation
References
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245–64.
- Hadziyannis S.J., Sette H.Jr., Morgan T.R., Balan V., Diago M., Marcellin P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140 (5): 346–55.
- Bruno R., Brunetti E., Maffezzini E. et al. Daily dose interferon for chronic hepatitis C: a prospective randomized study. Hepatology. 1998; 28: (4), pt. 2: 572A, abstr. 1637.
- Еналеева Д.Ш., Фазылов В.Х., Созинов А.С. Хронические вирусные гепатиты В, С и D. М.: «Медпресс-информ»; 2011: 257–9.
- Никитин И.Г., Гогова Л.М., Байкова И.Е. и др. Человеческий лейкоцитарный альфа-интерферон в комбинированной терапии больных хроническим гепатитом С, инфицированных не 1-м генотипом вируса. Клинические перспективы гастроэнтерологии, гепатологии. 2009; 1: 33–7.
- Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology. 2010; 138: 1338–45.
- Козина А.Н. Возможности персонифицированного подхода к лечению гепатита С на основании разработанных генетических тестов определения варианта полиморфизма гена ИЛ-28B / А.Н. Козина, Д.Д. Абрамов, Е.А. Климова и др. Лечащий врач. 2011; 10: 39–43.
- McCarthy J., Li J., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138: 2307–14.
- Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology. 2010; 138: 1338–45.
Supplementary files
